Abstract: Disclosed is an efficiency analysis method for an intelligent interaction system, including: obtaining user information and behavior data generated during execution of user commands, and associating the user information with the behavior data to obtain associated data; preprocessing the associated data, selecting efficiency indicators for the intelligent interaction system based on standard indicators, and classifying the preprocessed associated data according to the efficiency indicators to obtain classified data; formulating efficiency scoring criteria based on expert opinions, and obtaining efficiency scores of the classified data by using the efficiency scoring criteria; and determining weights of the efficiency scores by using an objective weight assignment method, and evaluating the efficiency scores through fuzzy comprehensive evaluation based on the weights to obtain comprehensive scores.

Abstract: A pyrimidine tricyclic derivative and a pharmaceutical application thereof. Specifically disclosed are a compound as represented by formula (I), a stereoisomer thereof, and a pharmaceutically acceptable salt thereof.

Abstract: A series of alkyl carboxylic acid compounds and an application thereof, and relates in particular to compounds represented by formula (II) and a pharmaceutically acceptable salt thereof.

Abstract: Provided is a fused tri-cyclic compound as PDE3/PDE4 dual inhibitor, and a use thereof in the preparation of drugs for PDE3/PDE4 associated diseases, particularly in medicinal functions such as chronic obstructive pulmonary disease (COPD). Provided are specifically a compound of formula (I) and a pharmaceutically acceptable salt thereof.

Abstract: Provided are a crystal form of a triazolopyridine-substituted indazole compound and a preparation method therefor; and specifically disclosed are a crystal form of a compound as represented by formula (I) and a preparation method therefor.

Abstract: Provided is a fused tri-cyclic compound as PDE3/PDE4 dual inhibitor, and a use thereof in the preparation of drugs for PDE3/PDE4 associated diseases, particularly in medicinal functions such as chronic obstructive pulmonary disease (COPD). Provided are specifically a compound of formula (I) and a pharmaceutically acceptable salt thereof.

Abstract: A compound represented by formula (III) or a pharmaceutically acceptable salt thereof, and disclosed is an application thereof in the preparation of a medication for treating diseases related to a CRBN receptor.

Abstract: A compound represented by formula (III) or a pharmaceutically acceptable salt thereof, and disclosed is an application thereof in the preparation of a medication for treating diseases related to a CRBN receptor.

Abstract: The present invention relates to a pyrimidine-based tricyclic compound and a use thereof, and specifically, relates to a pyrimidine-based tricyclic compound and a use thereof in preparation of a drug for treating a related disease. Specifically, disclosed are a compound represented by formula (II), a stereoisomer thereof, and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed is a benzopyrazole compound. Specifically disclosed are a compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a series of tricyclic furan-substituted piperidinedione compounds and an application thereof in preparing a drug for treating a disease related to CRBN protein. In particular, disclosed is a derivative compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: The present invention discloses a series of tricyclic compounds and use thereof in preparing a medicament for treating a disease related to CRBN protein. Specifically, the present invention discloses a derivative compound of formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: A cutter head structure includes a cutting edge portion including a cutting body. An outer surface of the cutting body is a curved surface which protrudes forwardly. The outer surface of the cutting body is provided with a first cutting edge and at least two second cutting edges. The first cutting edge extends from one side of the cutting body to a top region of the cutting body and then to the other side of the cutting body. The second cutting edges are respectively disposed on both sides of the first cutting edge. First chip flutes are defined between the first cutting edge and the second cutting edges adjacent thereto, and each of the first chip flutes has a width gradually increasing from the top region to both ends of the cutting body.

Abstract: Provided is a fused tri-cyclic compound as PDE3/PDE4 dual inhibitor, and a use thereof in the preparation of drugs for PDE3/PDE4 associated diseases, particularly in medicinal functions such as chronic obstructive pulmonary disease (COPD). Provided are specifically a compound of formula (I) and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a series of tricyclic furan-substituted piperidinedione compounds and an application thereof in preparing a drug for treating a disease related to CRBN protein. In particular, disclosed is a derivative compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase (e.g., CDK7), and therefore induce cellular apoptosis and/or inhibit transcription in the subject.

Abstract: The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase (e.g., CDK7), and therefore induce cellular apoptosis and/or inhibit transcription in the subject.